June 20, 2007

Contact:
Rebecca Howe
Genocea Biosciences
617.876.8191 ext. 200
Rebecca.Howe@genocea.com

VACCINE EXPERT GEORGE SIBER JOINS GENOCEA BIOSCIENCES AS EXECUTIVE CHAIRMAN

Former Wyeth Vaccines EVP and Chief Scientific Officer brings industry and academic experience to cutting edge vaccine company

Cambridge, MA – June 20, 2007 – Genocea Biosciences, a vaccine discovery and development company, today announced that it had hired George R. Siber, M.D. as Executive Chairman.

"Dr. Siber brings a tremendous depth of knowledge to the company," said Genocea President Robert Paull. "His vaccine experience will be instrumental in helping make our breakthrough development platform a commercial reality."

Dr. Siber is widely regarded as one of the leading global authorities in vaccines and was previously the Executive Vice President and Chief Scientific Officer of Wyeth Vaccines. While at Wyeth, Dr. Siber oversaw the development and approval of multiple widely-used childhood vaccines including an acellular pertussis vaccine (Acel-Imune), a meningococcal meningitis vaccine (Meningitec), and a pneumococcal vaccine (Prevnar). Prior to joining Wyeth, Dr. Siber was Director of the Massachusetts Public Health Biologic Laboratories and Harvard Medical School Associate Professor of Medicine at Dana Farber Cancer Institute. During this time, Dr. Siber oversaw research and manufacturing of multiple vaccines and immune globulins including Respigam, a human immune globulin against RSV, which was the precursor of Synagis.

In recognition of his contributions to this field, the recently completed $100 million Massachusetts Biologic Laboratory building for vaccine development and manufacturing was dedicated to Dr. Siber and his colleague Dr. Jeanne Leszczynski. Dr. Siber has authored more than 150 scientific articles in peer-reviewed journals and holds three issued patents. He has also served on numerous U.S. government and international advisory committees including the WHO/UNDP Steering Committee for Bacterial Vaccines, the Steering Committee for Development of Pneumococcal Vaccine for the Pan American Health Organization, the Institute of Medicine Committee on the Children's Vaccine Initiative and the NIH Blue Ribbon Panel for Bioterrorism and its Implications for Biomedical Research. He served as Chairman of the Scientific Review Committee of the U.S. Army's HIV research program in 2002 and 2006, serves on the Board of Scientific Counselors for the National Vaccine Center of the NIH, and the Advisory Board of the Massachusetts Biologic Laboratories, University of Massachusetts Medical School.

Dr. Siber brings his vast experience in vaccines to Genocea, which was formed in 2006 from technology developed at University of California at Berkeley by Dr. Darren Higgins. Dr. Higgins, currently Associate Professor of Microbiology and Molecular Genetics at Harvard Medical School co-founded Genocea with Associate Professor of Pathology at Harvard Medical School, Dr. David Sinclair and with leading venture capital firms Lux Capital Management of New York and Polaris Venture Partners of Boston. Genocea is focused on identifying antigens for the next generation of novel vaccines.

"Genocea's platform represents a powerful new technology to rapidly identify key $CD4^+$ and $CD8^+$ T-cell antigens in complex microorganisms or mammalian cells," said Siber. "The technology has the potential to discriminate protective from non-protective antigens and can enable rational rather than empiric selection, thereby dramatically accelerating the vaccine development process."

Dr. Siber will oversee Genocea's world-class Scientific Advisory Board, which includes Penny J. Hitchcock, D.V.M., Former Chief of Sexually Transmitted Diseases, National Institutes of Health; Ian Gust, Professorial Fellow, Department of Microbiology & Immunology, University of Melbourne; Peter Hutt, LL.M., Former Chief Legal Counsel, Food & Drug Administration; and Una S. Ryan, Ph.D., Chief Executive Officer, AVANT Immunotherapeutics.

June 20, 2007

"Genocea's high-throughput screening system removes the guesswork associated with designing vaccines to stimulate T-cell immunity," said co-founder Higgins. "Dr. Siber's scientific leadership and accomplishments in the vaccine industry will be a driving force in realizing the full potential of Genocea's technology."

About Genocea Biosciences:
Genocea Biosciences was founded in 2006 to commercialize key breakthroughs in vaccine discovery and development. Genocea can rapidly identify antigens that result in the *in vivo* stimulation of protective $CD8^+$ and $CD4^+$ T cells, targets that can be immediately incorporated into existing antigen delivery systems to produce multivalent vaccine formulations that have the highest probability of generating protective cell-mediated immunity. Investors include Lux Capital Management and Polaris Venture Partners. Visit www.genocea.com for more information.

# # #